Abstract: Disclosed are methods of preparing an isolated population of human papillomavirus (HPV)-specific T cells comprise dividing an HPV-positive tumor sample into multiple fragments; separately culturing the multiple fragments; obtaining T cells from the cultured multiple fragments; testing the T cells for specific autologous HPV-positive tumor recognition; selecting the T cells that exhibit specific autologous HPV-positive tumor recognition; and expanding the number of selected T cells to produce a population of HPV-specific T cells for adoptive cell therapy. Related methods of treating or preventing cancer using the T cells are also disclosed.
Type:
Application
Filed:
June 13, 2022
Publication date:
May 4, 2023
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Christian S. Hinrichs, Steven A. Rosenberg
Abstract: Provided are methods of preparing an enriched population of T cells having antigenic specificity for a target antigen. The method may comprise isolating T cells from a tumor sample of a patient; selecting the isolated T cells which have a gene expression profile; and separating the selected T cells from the unselected cells. The separated selected T cells provide an enriched population of T cells having antigenic specificity for the target antigen. Methods of isolating a T cell receptor (TCR), preparing a population of cells that express a TCR, isolated TCRs, isolated populations of cells, pharmaceutical compositions, and methods of treating or preventing a condition in a mammal are also provided.
Type:
Application
Filed:
March 19, 2021
Publication date:
May 4, 2023
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Sri Krishna, Frank J. Lowery, III, Ken-ichi Hanada, James C. Yang, Steven A. Rosenberg, Paul F. Robbins, Rami Yoseph
Abstract: Identification of immunodominant Babesia microti antigens using genome-wide immunoscreening is described. Candidate antigens were screened against sera from patients with clinical babesiosis. Also described are diagnostic assays with high sensitivity and specificity for detecting B. microti-specific antibodies in patient samples using the identified immunodominant antigens.
Type:
Grant
Filed:
November 1, 2018
Date of Patent:
May 2, 2023
Assignees:
The United States of America, as represented by the Secretary, Department of Health and Human Services, Yale University
Inventors:
Sanjai Kumar, Nitin Verma, Ankit Puri, Peter J. Krause
Abstract: An immunogen generally includes a virus-like particle and an antigen linked to the virus-like particle. The antigen includes an antigenic portion of a polypeptide, wherein the polypeptide inhibits lipoprotein lipase (LPL) activity by binding to LPL. In some embodiments, the polypeptide is at least a portion of angiopoietin-like 3 (ANGPTL3). In other embodiments, the polypeptide is at least a portion of angiopoietin-like 4 (ANGPTL4). In other embodiments, the polypeptide at least a portion of angiopoietin-like 8 (ANGPTL8). In some embodiments, the virus-like particle is a Qbeta immunogenic carrier. In some of these embodiments, the antigen is linked to the virus-like particle through a Gly-Gly-Gly-Cys linker at the C-terminal of the antigen.
Type:
Grant
Filed:
March 6, 2019
Date of Patent:
April 25, 2023
Assignees:
UNM Rainforest Innovations, The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Bryce Chackerian, Alan Remaley, Marcelo Amar, Alexandra Fowler
Abstract: The disclosure of a compound of Formula (I) or a pharmaceutically acceptable salt thereof (I) The variables W, R1, R2, R3, and R4 are defined in the disclosure. The disclosure provides a compound or salt of Formula (I) together with a pharmaceutically acceptable carrier. The disclosure also provides methods of treating a patient for Parkinson's disease and related syndromes, dyskinesia, especially dyskinesias secondary to treating Parkinson's disease with L-DOPA, neurodegenerative disorders such as Alzheimer's disease and dementia, Huntington's disease, restless legs syndrome, bipolar disorder and depression, schizophrenia, cognitive dysfunction, or substance use disorders, the methods comprising administering a compound of Formula I or salt thereof to the patient. The disclosure provides combination methods of treatment in which the compound of Formula (I) is administered to the patient together with one or more additional active agents.
Type:
Grant
Filed:
April 14, 2017
Date of Patent:
April 25, 2023
Assignees:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, THE UNIVERSITY OF KANSAS, THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL
Inventors:
David R. Sibley, Amy Elizabeth Moritz, R. Benjamin Free, Joseph P. Steiner, Noel Terrence Southall, Marc Ferrer, Xin Hu, Warren S. Weiner, Jeffrey Aubé, Kevin Frankowski
Abstract: Chimeric flaviviruses engineered to contain a reporter gene and chimeric nucleic acid molecules encoding the chimeric flaviviruses are described. The chimeric flaviviruses further include genomic non-coding regions, non-structural proteins, and at least a portion of a capsid (C) protein from West Nile virus (WNV), and premembrane (prM) and envelope (E) proteins from dengue virus (DENV). Diagnostic assays that utilize chimeric West Nile/dengue viruses are further described.
Type:
Grant
Filed:
August 17, 2018
Date of Patent:
April 25, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: A container comprising: a first panel; a second panel opposing the first panel; a first side; a second side opposing the first side; a third side; a fourth side opposing the third side; wherein each of the sides joins the first panel and the second panel; a chamber defined by the four sides, the first panel, and the second panel, wherein the chamber is configured to receive a biological specimen; a port defined in the first side; a plug inserted into the port; an opening defined in the second side; and a closure element coupled to the opening, wherein the chamber is leak proof.
Type:
Grant
Filed:
April 26, 2018
Date of Patent:
April 11, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Stephen M. Hewitt, Robert A. Star, Jeffrey C. Hanson, Hiroshi Kojima, Russell Bandle, Armando Filie
Abstract: Disclosed are compounds represented by the formula:(I), wherein R is as defined herein, and pharmaceutically acceptable salts thereof. Also disclosed are a method of treating a subject in need of treatment for a bacterial infection or a fungal infection, which includes administering to the subject an effective amount of one of the compounds or salts thereof. Further disclosed is a process for producing the compounds and salts thereof.
Type:
Application
Filed:
March 16, 2021
Publication date:
April 6, 2023
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Carole A. Bewley Clore, Hongbing Liu, Shannon I. Ohlemacher
Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.
Type:
Grant
Filed:
April 21, 2020
Date of Patent:
April 4, 2023
Assignee:
The United States of America,as represented by the Secretary, Department of Health and Human Services
Inventors:
Zhijian Wu, Anand Swaroop, Suja Hiriyanna, Tiansen Li
Abstract: The disclosure provides a method for synthesizing free base forms of (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine. In an embodiment synthesis of (2R,6R)-hydroxynorketamine (HNK) includes preparation of (R)-norketamine via chiral resolution from racemic norketamine via a chiral resolution with L-pyroglutamic acid. The disclosure also provided crystal forms of the corresponding (2R,6R)-hydroxynorketamine (HNK) and (2S,6S)-hydroxynorketamine hydrochloride salts.
Type:
Grant
Filed:
January 22, 2021
Date of Patent:
March 28, 2023
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Inventors:
Craig Thomas, Carlos Zarate, Ruin Moaddel, Todd Gould, Panos Zanos, Patrick Morris
Abstract: Methods and apparatus for calibrating radioactive sources are described. An array of scintillation detectors form a receptacle within which a sample or sample container can be retained by a holder. The scintillation detectors are coupled via light transducers such as photomultiplier tubes (PMTs) to independent electronic counters. Coincidence processing of time-tagged events yields a correlated event rate. One or more corrections can be applied as needed, for background counts, deadtime, or random coincidences. Voltage tuning of PMTs yields improved reproducibility. Variations are disclosed. 1% accuracy has been demonstrated over a range of 10 kBq-3 MBq, covering a gap in the capabilities of conventional technology.
Type:
Grant
Filed:
May 7, 2021
Date of Patent:
March 28, 2023
Assignee:
THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
Abstract: The invention provides an isolated or purified T-cell receptor (TCR) having antigenic specificity for MHC Class II-restricted MAGE-A3. The invention further provides related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells. Further provided by the invention are antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a mammal are further provided by the invention.
Type:
Application
Filed:
September 28, 2022
Publication date:
March 23, 2023
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Paul F. Robbins, Steven A. Rosenberg, Xin Yao
Abstract: Disclosed are isolated or purified T cell receptors (TCRs), wherein the TCRs have antigenic specificity for a mutated RAS amino acid sequence presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided.
Type:
Application
Filed:
February 12, 2021
Publication date:
March 16, 2023
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Noam Levin, Maria R. Parkhurst, Frank J. Lowery, III, Steven A. Rosenberg
Abstract: Disclosed is an isolated or purified T cell receptor (TCR), wherein the TCR has antigenic specificity for a mutated human RAS amino acid sequence with a substitution of glycine at position 12 with aspartic acid presented by a human leukocyte antigen (HLA) Class I molecule. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
Type:
Application
Filed:
February 12, 2021
Publication date:
March 16, 2023
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Noam Levin, Rami Yoseph, Biman Paria, Steven A. Rosenberg
Abstract: Embodiments of immunogens based on the HIV-1 Env fusion peptide and methods of their use and production are disclosed. Nucleic acid molecules encoding the immunogens are also provided. In several embodiments, the immunogens can be used to generate an immune response to HIV-1 Env in a subject, for example, to treat or prevent an HIV-1 infection in the subject.
Type:
Grant
Filed:
October 3, 2017
Date of Patent:
March 14, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter Kwong, Rui Kong, Tongqing Zhou, John Mascola, Kai Xu, Cheng Cheng, Gwo-Yu Chuang, Kevin Liu, Baoshan Zhang, Li Ou, Wing-Pui Kong
Abstract: Disclosed is a compound of formula (I): for treating or preventing a human immunodeficiency virus (HIV) infection in a mammal, for inhibiting or preventing maturation of an immature human immunodeficiency virus (HIV) to a mature HIV, and for preventing or inhibiting a human immunodeficiency virus (HIV) infection in a mammal having at least one HIV viral particle on a surface thereof.
Type:
Application
Filed:
December 17, 2020
Publication date:
March 2, 2023
Applicant:
The United States of America,as represented by the Secretary,Department of Health and Human Services
Inventors:
Daniel H. Appella, Herman Nikolayevskiy, Marco Robello, Michael T. Scerba
Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
Type:
Grant
Filed:
May 18, 2020
Date of Patent:
February 28, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
Abstract: Disclosed are compounds of formulas (I)-(IX) for treating or preventing a disease or disorder responsive to antagonism of a P2Y14R receptor agonist in a mammal in need thereof, wherein R1-R8, X, Y, Z, X?, Y?, Z?, and A are as defined herein, that are useful in treating an inflammatory such as asthma, cystic fibrosis, and sterile inflammation of the kidney.
Type:
Grant
Filed:
February 11, 2019
Date of Patent:
February 21, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Services
Abstract: Genetically modified compositions, such as non-viral vectors and T cells, for treating cancer are disclosed. Also disclosed are the methods of making and using the genetically modified compositions in treating cancer.
Type:
Grant
Filed:
August 26, 2020
Date of Patent:
February 21, 2023
Assignees:
Regents of the University of Minnesota, Intima Bioscience, Inc., The United States of America, as represented by the Secretary, Department of Health and Human Services
Inventors:
Branden Moriarity, Beau Webber, Modassir Choudhry, R. Scott McIvor, David Largaespada, Steven A. Rosenberg, Douglas C. Palmer, Nicholas P. Restifo
Abstract: A new chest X-ray database, referred to as “ChestX-ray8”, is disclosed herein, which comprises over 100,000 frontal view X-ray images of over 32,000 unique patients with the text-mined eight disease image labels (where each image can have multi-labels), from the associated radiological reports using natural language processing. We demonstrate that these commonly occurring thoracic diseases can be detected and spatially-located via a unified weakly supervised multi-label image classification and disease localization framework, which is validated using our disclosed dataset.
Type:
Grant
Filed:
March 26, 2018
Date of Patent:
February 21, 2023
Assignee:
The United States of America, as represented by the Secretary, Department of Health and Human Service
Inventors:
Xiaosong Wang, Yifan Peng, Le Lu, Zhiyong Lu, Ronald M. Summers